Business Context and Reporting Period
Company: Altria Group, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Altria operates a leading portfolio of tobacco products for U.S. consumers age 21+, including smokeable products (cigarettes, cigars), oral tobacco products (moist smokeless tobacco, nicotine pouches), and e-vapor products. The company is executing a strategy to transition adult smokers to smoke-free alternatives ("Moving Beyond Smoking"). Key subsidiaries include Philip Morris USA, UST LLC, Helix Innovations, and NJOY. The company also holds significant equity investments in Anheuser-Busch InBev (ABI) and Cronos Group Inc.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Revenues | $23.28 billion | $24.02 billion | (3.1%) |
| Operating Income | $9.90 billion | $11.24 billion | (11.9%) |
| Net Earnings (GAAP) | $6.95 billion | $11.26 billion | (38.3%) |
| Diluted EPS (GAAP) | $4.12 | $6.54 | (37.0%) |
| Adjusted Net Earnings | $9.15 billion | $8.94 billion | 2.4% |
| Adjusted Diluted EPS | $5.42 | $5.19 | 4.4% |
| Operating Cash Flow | $9.29 billion | $8.75 billion | 6.2% |
| Total Debt | $25.71 billion | $24.93 billion | 3.1% |
| Cash and Equivalents | $4.47 billion | $3.13 billion | 42.8% |
| Debt-to-Consolidated EBITDA | 2.0x | N/A | - |
Note: Adjusted metrics exclude special items such as asset impairments, litigation costs, and acquisition-related charges.
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 3.1% primarily due to lower shipment volumes in the smokeable products segment (cigarettes down 10.0%), partially offset by pricing actions.
- Significant Impairments: Reported net earnings were heavily impacted by non-cash impairments totaling $2.13 billion in the e-vapor segment (goodwill and definite-lived intangible assets) due to the ITC exclusion order on NJOY ACE and the proliferation of illicit e-vapor products. A $354 million impairment of the Skoal trademark occurred in 2024.
- Segment Performance:
- Smokeable Products: Revenues declined 3.4%; Adjusted Operating Companies Income (OCI) increased 1.3% driven by pricing and lower settlement charges.
- Oral Tobacco Products: Revenues increased 0.9%; Adjusted OCI increased 1.3% despite volume declines in moist smokeless tobacco (MST) offset by growth in nicotine pouches.
- E-Vapor Products: Reported a loss of $2.30 billion in OCI due to impairments and litigation costs related to the NJOY acquisition.
- Share Repurchases: The company repurchased approximately 17.1 million shares in 2025 under a $2.0 billion program, reducing shares outstanding and supporting EPS.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2028 Goals: Altria targets mid-single digit adjusted diluted EPS CAGR through 2028, a debt-to-EBITDA ratio of approximately 2.0x, and maintaining a total adjusted OCI margin of at least 60%.
- Smoke-Free Portfolio: Management continues to reassess smoke-free goals due to market disruption from illicit e-vapor products. They expect effective enforcement against illicit products to occur more gradually than initially anticipated.
- Optimize & Accelerate Initiative: A multi-phase initiative launched in 2024 aims to deliver cumulative savings of at least $600 million by the end of 2029 through process modernization and centralization.
- Dividends: The quarterly dividend was increased to $1.06 per share in Q3 2025. The company targets mid-single digit annual dividend growth through 2028.
Key Risks and Contingencies
- Illicit Trade: The proliferation of illicit flavored disposable e-vapor products (estimated at 70% of the category) is driving cigarette volume declines and negatively impacting the e-vapor business outlook.
- Regulatory and Litigation:
- ITC Orders: NJOY ACE is subject to exclusion and cease-and-desist orders prohibiting importation and sale in the U.S., pending appeal.
- Patent Litigation: Ongoing patent infringement lawsuits involving NJOY Daily and JUUL products.
- Health Care Litigation: Continued exposure to tobacco-related litigation, including Engle progeny cases and health care cost recovery actions.
- Consumer Behavior: Discretionary income pressures are driving consumers toward discount brands and cross-category movement to illicit products.
Investor Verification Checklist
- Impairment Assumptions: Verify the sensitivity of the e-vapor reporting unit's fair value to changes in discount rates and assumptions regarding the timing of enforcement against illicit e-vapor products.
- ITC Appeal Status: Monitor the progress of the appeal regarding the ITC exclusion order on NJOY ACE and potential outcomes for NJOY Daily patent litigation.
- Volume Trends: Track the rate of decline in domestic cigarette volumes versus the growth of illicit e-vapor products to assess the sustainability of the smokeable segment's pricing power.
- Debt Maturities: Review the schedule of long-term debt maturities, noting $1.57 billion due in 2026 and $1.22 billion in 2027.
- Regulatory Environment: Assess the impact of potential FDA actions on menthol cigarettes, flavored e-vapor products, and nicotine levels in combustible products.